We are experiencing 4 week turn-around time in review of submissions and resubmissions. We recommend commencing this process concurrently with your ethics submission and allowing at least 8 weeks for registration to be completed from date of first submission. We currently do not have the capacity to expedite reviews.

Note also there are delays to review of updates. We appreciate your patience.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT02412111




Registration number
NCT02412111
Ethics application status
Date submitted
3/04/2015
Date registered
8/04/2015
Date last updated
8/01/2019

Titles & IDs
Public title
A Phase 3 Study of Tezacaftor (VX-661) in Combination With Ivacaftor (VX-770) in Subjects Aged 12 Years and Older With Cystic Fibrosis (CF), Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to Ivacaftor
Scientific title
A Phase 3, Randomized, Double-Blind, Ivacaftor-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation and a Second CFTR Allele With a Gating Defect That Is Clinically Demonstrated to be Ivacaftor Responsive
Secondary ID [1] 0 0
VX14-661-109
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Cystic Fibrosis 0 0
Condition category
Condition code
Human Genetics and Inherited Disorders 0 0 0 0
Cystic fibrosis
Respiratory 0 0 0 0
Other respiratory disorders / diseases
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Inflammatory and Immune System 0 0 0 0
Connective tissue diseases
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Ivacaftor
Treatment: Drugs - Tezacaftor/Ivacaftor

Experimental: Ivacaftor (Run-in Period) - Ivacaftor 150 milligram (mg) tablet orally every 12 hours for 4 weeks.

Experimental: VX-661 + Ivacaftor (Active comparator period) - VX-661 100 mg and ivacaftor 150 mg fixed-dose combination tablet orally once daily in the morning and ivacaftor 150 mg tablet orally once daily in the evening for 8 weeks.

Active Comparator: Ivacaftor monotherapy (Active comparator period) - Ivacaftor 150 mg tablet orally every 12 hours as monotherapy for 8 weeks.


Treatment: Drugs: Ivacaftor


Treatment: Drugs: Tezacaftor/Ivacaftor


Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 8 - FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
Timepoint [1] 0 0
Baseline, Through Week 8
Secondary outcome [1] 0 0
Relative Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 8 - FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
Timepoint [1] 0 0
Baseline, Through Week 8
Secondary outcome [2] 0 0
Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score From Baseline Through Week 8 - The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.
Timepoint [2] 0 0
Baseline, Through Week 8
Secondary outcome [3] 0 0
Absolute Change From Baseline in Sweat Chloride Through Week 8 - Sweat samples were collected using an approved collection device.
Timepoint [3] 0 0
Baseline, Through Week 8
Secondary outcome [4] 0 0
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Timepoint [4] 0 0
Baseline up to Week 16
Secondary outcome [5] 0 0
Trough Plasma Concentrations (Ctrough) of VX-661, VX-661 Metabolites (M1-VX-661), Ivacaftor (IVA) and IVA Metabolite (M1-IVA)
Timepoint [5] 0 0
Predose on Week -2 for Run-in period; Pre-dose on Week 2 for Active comparator period

Eligibility
Key inclusion criteria
- Heterozygous for F508del-CFTR mutation and a second CFTR allele with a gating defect
that is clinically demonstrated to be ivacaftor responsive

- FEV1 =40% and =90% of predicted normal for age, sex, and height during screening

- Stable CF disease as judged by the investigator.
Minimum age
12 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- History of any comorbidity that, in the opinion of the investigator, might confound
the results of the study or pose an additional risk in administering study drug to the
subject.

- Pregnant and nursing females (females of childbearing potential must have a negative
pregnancy test at Screening and Week -4 Visits).

- Sexually active subjects of reproductive potential who are not willing to follow the
contraception requirements

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
- Chermside
Recruitment hospital [2] 0 0
- Clayton
Recruitment hospital [3] 0 0
- Melbourne
Recruitment hospital [4] 0 0
- South Brisbane
Recruitment hospital [5] 0 0
- Westmead
Recruitment postcode(s) [1] 0 0
- Chermside
Recruitment postcode(s) [2] 0 0
- Clayton
Recruitment postcode(s) [3] 0 0
- Melbourne
Recruitment postcode(s) [4] 0 0
- South Brisbane
Recruitment postcode(s) [5] 0 0
- Westmead
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
District of Columbia
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Indiana
Country [8] 0 0
United States of America
State/province [8] 0 0
Kentucky
Country [9] 0 0
United States of America
State/province [9] 0 0
Massachusetts
Country [10] 0 0
United States of America
State/province [10] 0 0
Michigan
Country [11] 0 0
United States of America
State/province [11] 0 0
Missouri
Country [12] 0 0
United States of America
State/province [12] 0 0
Nebraska
Country [13] 0 0
United States of America
State/province [13] 0 0
New Hampshire
Country [14] 0 0
United States of America
State/province [14] 0 0
New Jersey
Country [15] 0 0
United States of America
State/province [15] 0 0
New York
Country [16] 0 0
United States of America
State/province [16] 0 0
Ohio
Country [17] 0 0
United States of America
State/province [17] 0 0
Oklahoma
Country [18] 0 0
United States of America
State/province [18] 0 0
Oregon
Country [19] 0 0
United States of America
State/province [19] 0 0
Pennsylvania
Country [20] 0 0
United States of America
State/province [20] 0 0
South Carolina
Country [21] 0 0
United States of America
State/province [21] 0 0
Tennessee
Country [22] 0 0
United States of America
State/province [22] 0 0
Texas
Country [23] 0 0
United States of America
State/province [23] 0 0
Utah
Country [24] 0 0
United States of America
State/province [24] 0 0
West Virginia
Country [25] 0 0
Austria
State/province [25] 0 0
Innsbruck
Country [26] 0 0
Belgium
State/province [26] 0 0
Bruxelles
Country [27] 0 0
Belgium
State/province [27] 0 0
Gent
Country [28] 0 0
Belgium
State/province [28] 0 0
Leuven
Country [29] 0 0
Canada
State/province [29] 0 0
Calgary
Country [30] 0 0
Canada
State/province [30] 0 0
Toronto
Country [31] 0 0
Canada
State/province [31] 0 0
Vancouver
Country [32] 0 0
France
State/province [32] 0 0
Paris Cedex 14
Country [33] 0 0
Germany
State/province [33] 0 0
Dresden
Country [34] 0 0
Germany
State/province [34] 0 0
Erlangen
Country [35] 0 0
Germany
State/province [35] 0 0
Essen
Country [36] 0 0
Germany
State/province [36] 0 0
Frankfurt
Country [37] 0 0
Germany
State/province [37] 0 0
Giessen
Country [38] 0 0
Germany
State/province [38] 0 0
Heidelberg
Country [39] 0 0
Germany
State/province [39] 0 0
Jena
Country [40] 0 0
Germany
State/province [40] 0 0
Munchen
Country [41] 0 0
Ireland
State/province [41] 0 0
Cork
Country [42] 0 0
Ireland
State/province [42] 0 0
Dublin
Country [43] 0 0
Italy
State/province [43] 0 0
Bari
Country [44] 0 0
Italy
State/province [44] 0 0
Milano
Country [45] 0 0
Italy
State/province [45] 0 0
Roma
Country [46] 0 0
United Kingdom
State/province [46] 0 0
Belfast
Country [47] 0 0
United Kingdom
State/province [47] 0 0
Birmingham
Country [48] 0 0
United Kingdom
State/province [48] 0 0
Cardiff
Country [49] 0 0
United Kingdom
State/province [49] 0 0
Glasgow
Country [50] 0 0
United Kingdom
State/province [50] 0 0
Leeds
Country [51] 0 0
United Kingdom
State/province [51] 0 0
London
Country [52] 0 0
United Kingdom
State/province [52] 0 0
Manchester
Country [53] 0 0
United Kingdom
State/province [53] 0 0
Newcastle
Country [54] 0 0
United Kingdom
State/province [54] 0 0
Southampton

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Vertex Pharmaceuticals Incorporated
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a Phase 3, randomized, double-blind, ivacaftor-controlled, parallel-group,
multicenter study of tezacaftor in combination with ivacaftor in subjects aged 12 years and
older with CF who are heterozygous for the F508del-CFTR mutation and a second CFTR allele
with a gating defect that is clinically demonstrated to be ivacaftor responsive.
Trial website
https://clinicaltrials.gov/show/NCT02412111
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications